AxioMed will also be conducting a post-market study of the device’s treatment of cervical degenerative disc disease, and the results are expected to be used in a future Investigational Device Exemption to the FDA.
More Articles on Devices:
Dr. Jason Highsmith Performed First Precision Spectra Spinal Cord Stimulator Implant
Legislation to Repeal 2.3% Medical Device Tax Introduced in Senate
Smith & Nephew Profits Up 1% in 4Q, Revenue Dips 3%
